Beyond Air, Inc. (XAIR) Stock Price & Analysis
Beyond Air, Inc. (XAIR) fell 5.88% to USD 0.39 as of June 10, 2026 at 07:00 UTC, according to Nexqual real-time market data.
XAIR last closed at USD 0.41; the session ranged USD 0.39–0.44 on volume of 255,528 shares. Market capitalization is $4.90M, with a 52-week range of USD 0.38–5.84 (NCM). Source: Nexqual, June 10, 2026 at 07:00 UTC.
Key Statistics (as of June 10, 2026 at 07:00 UTC)
| Price | USD 0.39 |
|---|---|
| Change | ▼ 5.88% (down) |
| Previous Close | USD 0.41 |
| Open | USD 0.41 |
| Day Range | USD 0.39 – 0.44 |
| 52-Week Range | USD 0.38 – 5.84 |
| Volume | 255,528 shares |
| Market Cap | $4.90M |
| Exchange | NCM |
Technical Analysis (XAIR)
Nexqual's technical model rates XAIR "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:00 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 40.27 (neutral) |
| vs SMA50 | Below (USD 0.54) |
| MACD | -0.03 (negative) |
Analyst Ratings (XAIR)
Wall Street analysts rate XAIR "Buy" based on 2 analysts, with a mean price target of USD 8 (range USD 2–14), per Nexqual as of June 10, 2026 at 07:00 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 8 |
| High Target | USD 14 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 2 / 1 / 0 |
Earnings (XAIR)
| Revenue Estimate | $2.30M |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.85 vs est -0.54 ▼ miss |
| 2025-09-30 | USD -1.25 vs est -0.26 ▼ miss |
| 2025-06-30 | USD -1.53 vs est -1.32 ▼ miss |
| 2025-03-31 | USD -1.8 vs est -2.44 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:00 UTC.
Financials & Fundamentals (XAIR)
| Total Revenue | $6.92M |
|---|---|
| Revenue Growth (YoY) | +104.70% |
| Gross Margin | +1.82% |
| Operating Margin | -300.64% |
| Profit Margin | +0.00% |
| ROE | -240.21% |
| Debt / Equity | 284.71 |
| Current Ratio | 5.12 |
| Total Cash | $11.66M |
| Total Debt | $23.59M |
| Free Cash Flow | $-18.65M |
Source: Nexqual, June 10, 2026 at 07:00 UTC.
Financial Health Score (XAIR)
Nexqual rates Beyond Air, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:00 UTC.
| Growth | Strong — Revenue +220% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $12M cash vs $24M debt |
| Cash Flow | Weak — FCF negative: -$19M, burning cash |
| Efficiency | Critical — ROE -240%, ROA -51.2% |
Ownership (XAIR)
| Insider Ownership | +3.65% |
|---|---|
| Institutional Ownership | +11.41% |
| Shares Outstanding | 12.69M |
| Float | 10.30M |
| Short % of Float | +0.70% |
Source: Nexqual, June 10, 2026 at 07:00 UTC.
Leadership (XAIR)
Beyond Air, Inc. is led by Amir Avniel (age 51), Chief Executive Officer of NeuroNOS, per Nexqual as of June 10, 2026 at 07:00 UTC.
| Chief Executive Officer of NeuroNOS | Amir Avniel (age 51) |
|---|---|
| Chief Operating Officer | Michael A. Gaul (age 70) |
| CEO & Director | Robert Scott Goodman (age 59) |
| Chief Financial Officer | Daniel J. Moorhead (age 53) |
| Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board | Andrew R. Colin |
Major Backers & Investors (XAIR)
Notable institutional backers of Beyond Air, Inc. include Balyasny Asset Management LP, Murchinson Ltd., Daytona Street Capital LLC, according to Nexqual as of June 10, 2026 at 07:00 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Balyasny Asset Management LP | 3.52% |
| Murchinson Ltd. | 2.5% |
| Daytona Street Capital LLC | 1.19% |
| Fidelity | 1.04% |
| Bleichroeder LP | 0.66% |
| Lasry, Marc | 0.62% |
| Wealth Effects LLC | 0.21% |
| Jane Street Group, LLC | 0.21% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.21% |
| Vanguard Group | 0.7% |
Source: Nexqual, June 10, 2026 at 07:00 UTC.
From Beyond Air, Inc.'s Latest SEC 10-K Filing (filed 2025-06-20)
Key Strengths & Strategy (as disclosed to the SEC)
- Beyond Air has 88.2% ownership in NeuroNOS.       Our approved product and active pipeline of product candidates is shown in the tables below:           LungFit ® PH is the first FDA-approved system using our patented plasma pulse technology to generate on-demand NO from ambient air and, regardless of dose or flow, deliver it to a ventilator circuit.
- These studies suggest that adjuvant treatment combining NO with antibiotics might have a beneficial role by reducing bacterial infectivity, and therefore reduce the dependency on antibiotics.   Beyond Air Technology   We have developed the Beyond Air NO generator and delivery system which we call LungFit ® , a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer.
- Our system provides continuous monitoring and control of the gaseous content administered during intermittent and continuous NO inhalation treatments, as well as a precise and reliable monitoring system that is able to monitor patient status and alert medical staff to any adverse effects.   The LungFit ® system is innovatively designed to provide patients with a gaseous dose of NO (ranging from 0.5 ppm up to 400 ppm) combined with ambient air.
Partnerships
- To date, no such gas-based therapy has been approved for commercialization by the FDA or other regulatory agencies.   NeuroNos has entered into an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, LTD. to acquire the commercial rights for neuronal nitric oxide synthase (nNOS) inhibitors being developed for the treatment of autism spectrum disorder ("ASD") and other neurological conditions.
- On June 15, 2023, the Company announced that it has entered into an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, LTD. (the "University") to acquire the commercial rights for nNOS inhibitors being developed for the treatment of ASD and other neurological conditions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PAVM | PAVmed Inc. | USD 4.68 | ▼ 14.13% |
| CYCN | Cyclerion Therapeutics, Inc. | USD 3 | ▲ 0.67% |
| XFOR | X4 Pharmaceuticals, Inc. | USD 3.85 | ▲ 0.52% |
| PDSB | PDS Biotechnology Corporation | USD 1.03 | ▲ 0.98% |
| CYPH | Cypherpunk Technologies Inc. | USD 0.68 | ▲ 30.17% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:00 UTC. This page is informational and not investment advice.